Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$303.67
pos +1.17
+0.39%
Today's Range: 302.94 - 308.68 | BIIB Avg Daily Volume: 1,181,200
Last Update: 07/22/14 - 4:00 PM EDT
Volume: 1,199,243
YTD Performance: 8.77%
Open: $305.18
Previous Close: $302.50
52 Week Range: $203.55 - $358.89
Oustanding Shares: 237,199,825
Market Cap: 72,047,074,846
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 13 12 13
Moderate Buy 1 0 0 0
Hold 5 5 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.61 1.56 1.67 1.63
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 37.82
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
37.82 37.80 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.67% 35.58% 193.11%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $2.74 $2.84 $11.28 $15.23
Number of Analysts 2 2 2 2
High Estimate $2.80 $2.84 $11.69 $15.70
Low Estimate $2.67 $2.83 $10.87 $14.76
Prior Year $2.30 $2.34 $8.93 $11.28
Growth Rate (Year over Year) 18.91% 21.15% 26.32% 35.02%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Timothy Collins

 | Jul 7, 2014 | 2:33 PM EDT

This may be one of only two technical buying opportunities in 2014. 

updateBIIB Investor Mtg.

Jun 12, 2014 | 7:11 AM EDT

BIIB - Biogen Idec Inc. Annual Shareholder Meeting - 9AM

By

Jim Cramer

 | Jun 9, 2014 | 3:03 PM EDT

Become more aggressive about the real valuations of companies.

By

Jim Cramer

 | Jun 6, 2014 | 7:30 AM EDT

Shorts take much more homework than longs.

bullishBiogen Idec upgraded at JP Morgan

May 29, 2014 | 7:45 AM EDT

BIIB was upgraded from Neutral to Overweight, JP Morgan said. $375 price target. Company has multiple, mid-stage pipeline opportunities.

By

Ed Ponsi

 | May 28, 2014 | 10:30 AM EDT

After a decline, the sector has built a base, and these names are breaking out.

By

Jim Cramer

 | May 12, 2014 | 3:00 PM EDT

Away from the techs and the biotechs, you will find an astounding uniformity among stocks.

updateDeutsche Healthcare Conf.

May 7, 2014 | 7:02 AM EDT

Deutsche Bank Healthcare Conference

By

Dan Fitzpatrick

 | May 6, 2014 | 8:45 AM EDT

Take a step back from the noise and use only what you see on the charts.

By

Jim Cramer

 | Apr 28, 2014 | 4:00 PM EDT

When it gets as bad as it is now, we tend not to even care if a company is profitable.

We are currently testing the key resistance decision in ICE. Do not consider an entry with...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
EA reported June revenue of $775 mlm vs. $714 est. much better than expected. EPS of $0.19...
BIDU still has some higher targets, but it's a good idea to TRAIL UP stops when you EXTEND...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.